Suppr超能文献

聚(ADP-核糖)聚合酶-1 的天然抑制剂。

Natural inhibitors of poly(ADP-ribose) polymerase-1.

机构信息

Institute of Public Health and Environmental Protection, Batystowa 1B, 02-835 Warsaw, Poland.

出版信息

Mol Neurobiol. 2012 Aug;46(1):55-63. doi: 10.1007/s12035-012-8257-x. Epub 2012 Apr 4.

Abstract

Poly(ADP-ribose) polymerases (PARPs) are enzymes that catalyze the transfer of ADP-ribose units from β-nicotinamide adenine dinucleotide (NAD(+)) to acceptor proteins. PARP-1 is responsible for more than 90 % of protein poly-ADP-ribosylation in the brain and may play a role as a molecular switch for cell survival and death. The functional roles of PARP-1 are largely mediated by its activation after binding to damaged DNA. Upon binding, PARP-1 activity increases rapidly and cleaves NAD(+) into ADP-ribose and nicotinamide. Increased activity of PARP-1 can promote DNA repair and its interaction with several transcription factors, whereas hyperactivation of PARP-1 can result in poly(ADP-ribose) accumulation and depletion of NAD(+) and ATP which may lead to caspase independent apoptotic or necrotic cell death, respectively. Excessive PARP-1 activity has been implicated in the pathogenesis of numerous clinical conditions such as stroke, myocardial infarction, inflammation, diabetes, and neurodegenerative disorders. Therefore, it is not surprising that the search for PARP-1 inhibitors with specific therapeutic uses (e.g., brain ischemia, cancer) has been an active area of research. Beyond medicinal uses, naturally occurring PARP-1 inhibitors may also offer a unique preventative means at attenuating chronic inflammatory diseases through dietary supplementation. This possibility has prompted research for specific, naturally occurring inhibitors of PARP-1. Though fewer investigations focus on identifying endogenous inhibitors/modulators of PARP-1 activity in vivo, these activities are very important for better understanding the complex regulation of this enzyme and the potential long-term benefits of supplementation with PARP-1 inhibitors. With this in mind, the focus of this article will be on providing a state-of-the-science review on endogenous and naturally occurring compounds that inhibit PARP-1.

摘要

聚(ADP-核糖)聚合酶(PARPs)是一种酶,能够催化β-烟酰胺腺嘌呤二核苷酸(NAD(+))上的 ADP-核糖单位转移到受体蛋白上。PARP-1 负责大脑中超过 90%的蛋白质多 ADP-核糖基化,可能作为细胞存活和死亡的分子开关发挥作用。PARP-1 的功能作用主要通过与受损 DNA 结合后的激活来介导。结合后,PARP-1 活性迅速增加,并将 NAD(+)切割成 ADP-核糖和烟酰胺。PARP-1 活性的增加可以促进 DNA 修复及其与几种转录因子的相互作用,而 PARP-1 的过度激活会导致聚(ADP-核糖)积累和 NAD(+)和 ATP 的耗竭,这可能分别导致 caspase 非依赖性凋亡或坏死性细胞死亡。过量的 PARP-1 活性与许多临床病症的发病机制有关,如中风、心肌梗死、炎症、糖尿病和神经退行性疾病。因此,寻找具有特定治疗用途(如脑缺血、癌症)的 PARP-1 抑制剂一直是一个活跃的研究领域,这并不奇怪。除了药用用途外,天然存在的 PARP-1 抑制剂也可能通过饮食补充提供一种独特的预防慢性炎症性疾病的手段。这种可能性促使人们研究特定的、天然存在的 PARP-1 抑制剂。尽管较少的研究关注在体内鉴定 PARP-1 活性的内源性抑制剂/调节剂,但这些活性对于更好地理解该酶的复杂调控以及补充 PARP-1 抑制剂的潜在长期益处非常重要。考虑到这一点,本文的重点将是提供关于内源性和天然存在的抑制 PARP-1 的化合物的最新科学综述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验